Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 31, 2022 - Issue 2
Submit an article Journal homepage
638
Views
3
CrossRef citations to date
0
Altmetric
Review

Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials

Pankaj Aggarwala Independent authorView further author information
,
Mazen Noureddinb Cedars Sinai Medical Center, Los AngelesView further author information
,
Stephen Harrisonc Pinnacle Clinical Research, San AntonioView further author information
,
Sophie Jeannind Summit Clinical Research, San AntonioView further author information
&
Naim Alkhourie Arizona Liver Health, ChandlerCorrespondence[email protected]
View further author information
Pages 163-172 | Received 05 Nov 2021, Accepted 19 Jan 2022, Published online: 10 Feb 2022

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Lampros Chrysavgis, Ilias Giannakodimos, Antonios Chatzigeorgiou, Konstantinos Tziomalos, George Papatheodoridis & Evangelos Cholongitas. (2022) The role of fibroblast growth factor 19 in the pathogenesis of nonalcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 16:9, pages 835-849.
Read now

Articles from other publishers (2)

Josep M. Llovet, Catherine E. Willoughby, Amit G. Singal, Tim F. Greten, Mathias Heikenwälder, Hashem B. El-Serag, Richard S. Finn & Scott L. Friedman. (2023) Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nature Reviews Gastroenterology & Hepatology 20:8, pages 487-503.
Crossref
Cong Liu, Milena Schönke, Borah Spoorenberg, Joost M Lambooij, Hendrik JP van der Zande, Enchen Zhou, Maarten E Tushuizen, Anne-Christine Andreasson, Andrew Park, Stephanie Oldham, Martin Uhrbom, Ingela Ahlstedt, Yasuhiro Ikeda, Kristina Wallenius, Xiao-Rong Peng, Bruno Guigas, Mariëtte R Boon, Yanan Wang & Patrick CN Rensen. (2023) FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis. eLife 12.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.